This study aims to evaluate the effectiveness of a new treatment for Diabetic Macular Edema, a condition where swelling occurs in the central part of the retina, which is the light-sensitive layer at the back of the eye. The research compares a new medication called EYP-1901, which is a tyrosine kinase inhibitor delivered via an implant, against aflibercept, which is provided as a liquid injection into the eye. The implant is a small device placed inside the eye to release medicine over time, while the other treatment is a standard solution for injection.

During the study, participants will receive either the new implant or the standard injection. The process involves monitoring changes in best corrected visual acuity, which refers to the clearest vision a person can achieve with glasses or contact lenses. Researchers will also observe changes in the thickness of the retina and how well participants can read letters on an eye chart over a period of time. The study will track how often additional treatments are required and how the swelling in the eye responds to the different options provided.